Blog
RSS FeedPosted by Michael Wonder on 14 Jun 2022
ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 02 Jun 2022
ICER publishes evidence report on gene therapy for beta thalassaemia
2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...
Posted by Michael Wonder on 13 Apr 2022
ICER releases draft evidence report on gene therapy for beta thalassaemia
13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 28 Mar 2022
ICER publishes evidence report on treatments for COVID-19
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...
Posted by Michael Wonder on 17 Mar 2022
ICER publishes evidence report on novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects
17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced ...
Posted by Michael Wonder on 05 Feb 2022
Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits
3 February 2022 - The prices of drugs used to treat COVID-19 for those at risk of serious illness are ...
Posted by Michael Wonder on 25 Jan 2022
ICER releases draft evidence report on novel agents to prevent chemotherapy-induced neutropenia
25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...
Posted by Michael Wonder on 06 Jan 2022
ICER publishes evidence report on tirzepatide for type 2 diabetes
6 January 2022 - Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as ...
Posted by Michael Wonder on 09 Nov 2021
ICER releases draft evidence report on tirzepatide for type 2 diabetes mellitus
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 04 Nov 2021
ICER publishes evidence report on tezepelumab for severe asthma
4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic ...
Posted by Michael Wonder on 20 Oct 2021
ICER publishes final evidence report and policy recommendations on therapies for myasthenia gravis
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...
Posted by Michael Wonder on 17 Sep 2021
ICER releases draft evidence report on therapies for severe asthma
16 September 2021 - Public comment period now open until 14 October 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 10 Sep 2021
ICER publishes evidence report on treatments for myasthenia gravis
10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...
Posted by Michael Wonder on 18 Aug 2021
ICER releases draft evidence report on mavacamten for hypertrophic cardiomyopathy
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 22 Jul 2021
ICER releases draft evidence report on therapies for myasthenia gravis
22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting ...